KANSAS CITY, Kan., Jan. 4, 2018 /PRNewswire/ -- Cingulate Therapeutics LLC, a clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing its precision timed release drug delivery platform technology, today announced the acceptance of data from its proof of concept clinical trial of CTX-1301 for poster presentation at the 2018 APSARD Annual Meeting. The conference, which will be held by the American Professional Society of ADHD and Related Disorders, will take place at the Washington Marriott Wardman Park in Washington D.C. from January 12-14, 2018. The presentation will mark the final release of data from a study conducted in 2017 evaluating CTX-1301, Cingulate's proprietary, first-line stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), utilizing an innovative, proprietary timed release technology OralogiK™ developed by Cingulate Therapeutics' partner BDD.
|
Poster Number: |
69 | |
|
Title: |
Pharmacoscintigraphic and Pharmacokinetic Analysis of CTx-1301, a Novel Tri-Modal Oral Formulation for Release of Dexmethylphenidate in Healthy Adults | |
|
Investigators: |
Raul R. Silva, MD, Matt Brams, MD, Arthur Straughn, PharmD, Shane J. Schaffer, PharmD, Steven Abele, Howard Stevens, PhD, Neil Masson, MD | |
|
Day & Time: |
Saturday, January 13; 12:30 PM – 2:30 PM | |
|
Location: |
Washington Marriott Wardman Park; Exhibit Hall C | |
About Cingulate Therapeutics
Cingulate Therapeutics LLC is a privately held clinical stage biopharmaceutical company focused on the development of new and innovative products utilizing the Company's innovative drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Cingulate is developing two proprietary, first-line stimulant medications, CTX-1301 (dexmethylphenidate) and CTX-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTX-1301 and CTX-1302 utilize an innovative, flexible core tableting technology with a Target Product Profile designed to deliver a rapid onset and last the entire active day while minimizing the afternoon crash and impact on sleep and appetite. The Company has completed a Proof of Concept Phase I clinical trial and plans to implement the full clinical plan for both CTX-1301 and CTX-1302 in early 2018. Cingulate anticipates filing INDs for both products in the first quarter of 2018 and will pursue approval via the accelerated 505(b)(2) regulatory pathway. The company has offices in Kansas City, KS and Morristown, NJ. For more information visit www.cingulatetherapeutics.com.
For Investors & Media:
Tiberend Strategic Advisors, Inc. on behalf of Cingulate Therapeutics
Jonathon Brzezinski, Ph.D.: jbrzezinski@tiberend.com; (212) 375-2681
Janine McCargo: jmccargo@tiberend.com; (646) 604-5150
SOURCE Cingulate Therapeutics LLC